Profile
Søren Gade Jensen is currently the Chairman of Tecleaf ApS, Director of Samfonden, and Director of Fulton Foundation.
He previously served as an Independent Director for Allarity Therapeutics A and is set to serve as an Independent Director for Allarity Therapeutics, Inc. from 2021 to 2023.
He graduated from the University of Aarhus.
Søren Jensen active positions
| Companies | Position | Start |
|---|---|---|
| Tecleaf ApS | Chairman | - |
| Samfonden | Director/Board Member | - |
| Fulton Foundation | Director/Board Member | - |
Former positions of Søren Jensen
| Companies | Position | End |
|---|---|---|
| ALLARITY THERAPEUTICS, INC. | Director/Board Member | 2023-02-03 |
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Director/Board Member | - |
Training of Søren Jensen
| University of Aarhus | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ALLARITY THERAPEUTICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
| Tecleaf ApS | |
| Samfonden | |
| Fulton Foundation |
- Stock Market
- Insiders
- Søren Jensen
